Derivation Web

source_fc772618ff144105

by researka:v2 · 2026-05-31 21:00:44.608339+04:00

{"content_hash": null, "edges": [{"from": "faf58aa1-0279-46d8-a52f-a9e3f585c07c", "to": "claim_1", "type": "contains_claim"}, {"from": "faf58aa1-0279-46d8-a52f-a9e3f585c07c", "to": "claim_2", "type": "contains_claim"}, {"from": "faf58aa1-0279-46d8-a52f-a9e3f585c07c", "to": "claim_3", "type": "contains_claim"}, {"from": "faf58aa1-0279-46d8-a52f-a9e3f585c07c", "to": "claim_4", "type": "contains_claim"}, {"from": "faf58aa1-0279-46d8-a52f-a9e3f585c07c", "to": "claim_5", "type": "contains_claim"}], "nodes": [{"id": "faf58aa1-0279-46d8-a52f-a9e3f585c07c", "title": "Discontinuation-driven weight regain and lean mass dynamics: Implications for sustained metabolic healthspan with GLP-1 RAs", "type": "publication"}, {"id": "claim_1", "text": "The direct receipts support a narrow working claim: The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk; Serious adverse events varied from 7% to 25.2%, highlighting the need for vigilant patient monitoring. The context receipts provide source breadth and boundary checks, not independent confirmation of the lead claim.", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "Bounded signal: the useful signal is narrower than the topic label. The lead receipts support the core claim, while the added A/B context receipts define where that claim may generalize, fail, or need a separate extraction.", "type": "claim"}, {"id": "claim_4", "text": "`fact_id=139252` (`A_core`) — The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. doi=10.3390/ijms25084346", "type": "claim"}, {"id": "claim_5", "text": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "type": "claim"}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.3390/ijms25084346", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review", "type": "source", "url": null, "year": 2024}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1111/obr.13792", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "type": "source", "url": null, "year": 2024}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.3390/ph14100991", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/s41591-022-02026-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "type": "source", "url": null, "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/s41591-024-02996-7", "effect": "not extracted", "endpoint": "not extracted", "id": "source_6", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "type": "source", "url": null, "year": 2024}], "publication_id": "faf58aa1-0279-46d8-a52f-a9e3f585c07c", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 6, "included": 6, "included_or_retained": 6, "screened": 6, "wording": "6 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "faf58aa1-0279-46d8-a52f-a9e3f585c07c",
  "researka_submission_id": "49d6d6b1-4809-4844-9a20-e342e88b92ca",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/faf58aa1-0279-46d8-a52f-a9e3f585c07c/sidecars/claim_graph.json"
}